Arcutis Biotherapeutics (ARQT) Income from Continuing Operations (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Income from Continuing Operations of 11295000.0 for Q1 2026, up 54.93% year-over-year from 7290475.21 in Q1 2025, and down 165.04% quarter-over-quarter from 17366000.0 in Q4 2025.
Powered by 
Analysis
Arcutis Biotherapeutics (ARQT) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 11295000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 54.93% year-over-year to 11295000.0; the TTM figure through Mar 2026 stood at 2405000.0 (up 98.15% YoY), while the FY2025 annual figure was 16170000.0, up 88.45% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 11295000.0, down from 17366000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 17366000.0 in Q4 2025, with the low at 107709000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 44765000.0 (2023), against an average of 43686000.0.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 88.76% in 2022, then soared 260.98% in 2025.
- Arcutis Biotherapeutics' Income from Continuing Operations stood at 72019000.0 in 2022, then rose by 7.96% to 66284000.0 in 2023, then surged by 83.72% to 10788000.0 in 2024, then jumped by 260.98% to 17366000.0 in 2025, then slumped by 165.04% to 11295000.0 in 2026.
- Business Quant data shows ARQT's Income from Continuing Operations at 11295000.0 in Q1 2026, 17366000.0 in Q4 2025, and 7410000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.12 Bn | 2.88 Bn | 118.92 Mn | 15.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.01 Mn |
| Mar 31, 2026 | -11.30 Mn |
| Dec 31, 2025 | 17.37 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | -15.89 Mn |
| Mar 31, 2025 | -25.06 Mn |
| Dec 31, 2024 | -10.79 Mn |
| Sep 30, 2024 | -41.54 Mn |
| Jun 30, 2024 | -52.33 Mn |
| Mar 31, 2024 | -35.38 Mn |
| Dec 31, 2023 | -66.28 Mn |
| Sep 30, 2023 | -44.77 Mn |
| Jun 30, 2023 | -70.99 Mn |
| Mar 31, 2023 | -80.10 Mn |
| Dec 31, 2022 | -72.02 Mn |
| Sep 30, 2022 | -107.71 Mn |
| Jun 30, 2022 | -68.06 Mn |
| Mar 31, 2022 | -65.23 Mn |
| Dec 31, 2021 | -71.52 Mn |
| Sep 30, 2021 | -57.06 Mn |